547 related articles for article (PubMed ID: 17060208)
41. Optimizing randomized phase II trials assessing tumor progression.
Stone A; Wheeler C; Carroll K; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):146-52. PubMed ID: 16807129
[TBL] [Abstract][Full Text] [Related]
42. Phase II trials powered to detect tumor subtypes.
Roberts JD; Ramakrishnan V
Clin Cancer Res; 2011 Sep; 17(17):5538-45. PubMed ID: 21737510
[TBL] [Abstract][Full Text] [Related]
43. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.
Tang H; Foster NR; Grothey A; Ansell SM; Goldberg RM; Sargent DJ
J Clin Oncol; 2010 Apr; 28(11):1936-41. PubMed ID: 20212253
[TBL] [Abstract][Full Text] [Related]
44. Tumor shrinkage and objective response rates: gold standard for oncology efficacy screening trials, or an outdated end point?
Bradbury P; Seymour L
Cancer J; 2009; 15(5):354-60. PubMed ID: 19826353
[TBL] [Abstract][Full Text] [Related]
45. Targeting population entering phase III trials: a new stratified adaptive phase II design.
Tournoux-Facon C; De Rycke Y; Tubert-Bitter P
Stat Med; 2011 Apr; 30(8):801-11. PubMed ID: 21432875
[TBL] [Abstract][Full Text] [Related]
46. [Phase III study--current status and problems].
Negoro S; Fukuoka M
Gan To Kagaku Ryoho; 1991 Jul; 18(9):1505-9. PubMed ID: 1649581
[TBL] [Abstract][Full Text] [Related]
47. Phase II stopping rules that employ response rates and early progression.
Goffin JR; Tu D
J Clin Oncol; 2008 Aug; 26(22):3715-20. PubMed ID: 18669457
[TBL] [Abstract][Full Text] [Related]
48. Clinical safety evaluation of combination vaccines.
Midthun K; Horne AD; Goldenthal KL
Dev Biol Stand; 1998; 95():245-9. PubMed ID: 9855438
[TBL] [Abstract][Full Text] [Related]
49. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ
J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470
[No Abstract] [Full Text] [Related]
50. Sample size tables for exact single-stage phase II designs.
A'Hern RP
Stat Med; 2001 Mar; 20(6):859-66. PubMed ID: 11252008
[TBL] [Abstract][Full Text] [Related]
51. Alternative designs of phase II trials considering response and toxicity.
Jin H
Contemp Clin Trials; 2007 Jul; 28(4):525-31. PubMed ID: 17428744
[TBL] [Abstract][Full Text] [Related]
52. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients.
Freidlin B; Simon R
Clin Cancer Res; 2005 Nov; 11(21):7872-8. PubMed ID: 16278411
[TBL] [Abstract][Full Text] [Related]
53. Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT).
Booth CM; Calvert AH; Giaccone G; Lobbezoo MW; Eisenhauer EA; Seymour LK
Eur J Cancer; 2008 Jan; 44(1):25-9. PubMed ID: 17845846
[TBL] [Abstract][Full Text] [Related]
54. Design of Phase II cancer trials for evaluation of cytostatic/cytotoxic agents.
Kocherginsky M; Cohen EE; Karrison T
J Biopharm Stat; 2009; 19(3):524-9. PubMed ID: 19384693
[TBL] [Abstract][Full Text] [Related]
55. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
56. Newer phase II trial designs gaining ground.
Benowitz S
J Natl Cancer Inst; 2007 Oct; 99(19):1428-9. PubMed ID: 17895467
[No Abstract] [Full Text] [Related]
57. Designing phase II studies in cancer with time-to-event endpoints.
Owzar K; Jung SH
Clin Trials; 2008; 5(3):209-21. PubMed ID: 18559409
[TBL] [Abstract][Full Text] [Related]
58. Improving the decision to pursue a phase 3 clinical trial by adjusting for patient-specific factors in evaluating phase 2 treatment efficacy data.
Heller G; Kattan MW; Scher HI
Med Decis Making; 2007; 27(4):380-6. PubMed ID: 17761958
[TBL] [Abstract][Full Text] [Related]
59. Sequential designs for phase III clinical trials incorporating treatment selection.
Stallard N; Todd S
Stat Med; 2003 Mar; 22(5):689-703. PubMed ID: 12587100
[TBL] [Abstract][Full Text] [Related]
60. One- and two-stage designs for stratified phase II clinical trials.
London WB; Chang MN
Stat Med; 2005 Sep; 24(17):2597-611. PubMed ID: 16118809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
